Envista Holdings Corporation announced that its Board of Directors appointed Paul Keel, currently President and Chief Executive Officer, to serve as Chairman of the Board effective August 19, 2026. Concurrently, Scott Huennekens was appointed Lead Independent Director. The Compensation Committee approved a $200,000 annual base salary increase for Mr. Keel, raising it from $1.1 million to $1.3 million, effective August 24, 2026. Additionally, the Board granted Mr. Keel a special one-time equity award valued at $10 million on the grant date of August 18, 2026, consisting of $5 million in time-based restricted stock units vesting over four years and $5 million in performance-based restricted stock units tied to total shareholder return relative to the S&P 400 Health Care Sector Index. A separate special one-time equity award valued at $1.5 million in performance-based restricted stock units was granted to Chief Financial Officer Eric Hammes under identical performance conditions. Envista Holdings Corporation operates in the dental industry, providing diagnostic and treatment solutions.

Envista Holdings Corporation reported second quarter 2026 financial results for the period ended July 3, 2026. Sales reached $731 million, reflecting 5.0% core sales growth compared to the prior year. GAAP diluted earnings per share were $0.33, while adjusted diluted EPS rose 58% year-over-year to $0.41. Adjusted EBITDA increased 28% to $108 million with a margin of 14.7%. The company raised its full-year 2026 outlook for core sales growth to 3.5%-4.5%, adjusted EBITDA growth to 11%-14%, and adjusted diluted EPS to $1.50-$1.55. During the quarter, Envista repurchased 2.4 million shares for approximately $59 million, leaving $283 million in remaining capacity under its stock repurchase program. Envista is a global leader in the dental industry providing technologies, consumables, and services to dental professionals.